-
Story /Cardiovascular disease is the leading cause of death in the US, claiming one in four lives. Social factors such as living conditions, education and diet play a key role in determining a person’s heart health, which means cardiovascular disease typically hits vulnerable communities the hardest. Our three-year Closing the Gap initiative with the Jefferson Collaborative for Health Equity (established by Jefferson Health and Thomas Jefferson University) focuses on addressing the upstream social determinants of heart health in five vulnerable neighborhoods in Philadelphia with high rates of stroke and adverse outcomes related to heart disease.
-
Featured News /We’re thrilled to announce that Novartis, a proudly Swiss company, is an official partner of the Eurovision Song Contest 2025, hosted in our headquarters city of Basel, Switzerland.
-
Statement /
-
Press release /Basel, April 4, 2019 - Novartis announced today that there is a legal dispute with Amgen regarding the collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of…
-
Press release /Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim Pegfilgrastim is used to reduce the incidence of neutropenia, one…
-
Press release /Basel, December 7, 2017 -Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of…
-
Story /Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.
-
Press release /Basel, December 6, 2021 — The bilateral transaction between Novartis and Roche for the sale of 53.3 million (approximately 33%) Roche bearer shares has successfully closed today, December 6, 2021.…
-
Media Library /
Pagination
- ‹ Previous page
- 1
- …
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- …
- 204
- › Next page